Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

By / 05/06/2023

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that new data will be presented on TG4001.